Publicaciones en colaboración con investigadores/as de Hospital Universitario de Cruces (37)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Natural history and surgical outcomes of Rathke’s cleft cysts: a Spanish multicenter study

    Frontiers in Endocrinology, Vol. 15

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population

    The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

2021

  1. Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply

    Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121

  2. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al

    Clinical and experimental rheumatology

  3. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  4. Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

  2. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study

    Clinical and experimental rheumatology, Vol. 37, Núm. 3, pp. 437-444

  3. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  4. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 90-96

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, singleblind, placebo-controlled phase Ib/IIa clinical trial

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 196-202